Summary & Overview
HCPCS J1000: Injection, Depo-Estradiol Cypionate, Up to 5 mg
HCPCS Level II code J1000 designates the injection of depo-estradiol cypionate, up to 5 mg, a long-acting intramuscular estrogen preparation used in hormone therapy. This national-level code is used by clinicians and facilities to bill for single-dose administration of this medication and matters for consistent claims adjudication, coverage determination, and clinical documentation nationwide.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines payer coverage patterns, common billing practices, and areas where coding clarity affects payment and utilization reporting.
Readers will find benchmarks for utilization and reimbursement patterns where available, summaries of relevant policy considerations affecting coverage and prior authorization, and clinical context explaining typical use cases and sites of service. The report also identifies common payer requirements for documentation and outlines practical implications for billing staff and revenue cycle teams.
Data not available in the input is noted where specific payer policy details, associated ICD-10 diagnoses, taxonomies, and related codes would normally be provided.
Billing Code Overview
HCPCS Level II code J1000 describes an injection of depo-estradiol cypionate, up to 5 mg. This code represents a single-dose medication administration for a long-acting estrogen formulation supplied for intramuscular injection.
Service Type: Medication administration – hormone therapy injection
Typical Site of Service: Outpatient clinic or physician office; may also be administered in ambulatory surgical centers or community health centers depending on clinical setting
Clinical & Coding Specifications
Clinical Context
A typical patient is a postmenopausal woman or a transgender female receiving intramuscular hormone therapy for estrogen replacement using depo-estradiol cypionate, up to 5 mg per injection. The clinical workflow begins with an outpatient consultation in a primary care, endocrinology, gynecology, or gender-health clinic where the indication, risks, and dosing schedule are documented. A clinician or licensed injector performs the visit, obtains informed consent, verifies allergies and medication list, documents baseline vitals, and prepares the syringe. The injection is administered intramuscularly (commonly in the gluteal or deltoid muscle) in a procedure room or treatment area. Post-injection observation is brief (minutes) for immediate adverse effects. Documentation includes the drug name J1000, dosage administered, lot number, route, site, and any relevant counseling. Follow-up visits are scheduled to monitor therapeutic response, hormone levels, and adverse events, and to document subsequent injections in the medical record and claims submission.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier (default) | Use when no specific modifier applies and service is billed normally. |
11 |